Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism

Victoria Ekstrom1,*, Rajneesh Kumar1, Yi Zhao2, Mei Ling Yee3, Cynthia Sung4,5, Dorothy Toh4, Poh Yen Loh6, Jessica Tan6, Eng Kiong Teo6, Wan Cheng Chow1

1Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, 2Department of Clinical Translational Research, Singapore General Hospital, Singapore, 3Department of Pharmacy, Singapore General Hospital, Singapore, 4Health Products Regulation Group, Health Sciences Authority, Singapore, 5Emerging Infectious Disease Programme, Duke-NUS Medical School, Singapore and 6Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore

*Corresponding author. Department of Gastroenterology and Hepatology, Singapore General Hospital, Outram Road Singapore 169608, Singapore. Tel: +65-98774539; E-mail: vekstrom@gmail.com

Abstract

Background and aim: Conventional hepatitis C treatment using pegylated interferon (PEG-IFN) and ribavirin is associated with significant side effects. IL28B polymorphism can predict response to treatment, with CC genotype having a better response. ITPA gene deficiency protects against clinically significant anaemia induced by treatment. The purpose of this study was to determine IL28B polymorphism and ITPA variation among hepatitis C genotype 1 patients who have undergone therapy with PEG-IFN and ribavirin and their association with sustained viral response (SVR).

Methods: All hepatitis C genotype 1 patients who had been treated with PEG-IFN and ribavirin over the past 10 years were identified by available medical records and were contacted by letter of invitation to participate in the study. Blood samples for IL28B and ITPA genotyping were obtained. Medical records were reviewed for verification of treatment response, development of anaemia and if treatment reduction was required during the treatment.

Results: A total of 61 patients with hepatitis C genotype 1 were treated with PEG-IFN and ribavirin, of whom 42 agreed to participate in the study. Mean age was 45.6±12.9 years at time of treatment, and 83.3% of patients were males. Thirty-three (78.6%) had IL28B CC genotype, of whom 25 (75.8%) obtained SVR compared with only 3 of 9 (33.3%) non C/C genotype patients who achieved SVR (P=0.041). Eleven (26.1%) patients had ITPA AC genotype, and 30 (71.4%) had CC genotype. There was no statistically significant difference between ITPA AC and CC genotypes in predicting clinically significant anaemia (45.5% vs 63.3%, P=0.302). Even among patients who developed anaemia, 70.8% still managed to achieve SVR. Treatment reduction also had no impact on SVR.

Conclusion: Hepatitis C genotype 1 patients should be informed of the response rate for treatment with PEG-IFN and ribavirin in a population with favourable IL28B genotype before consideration of newer therapeutic options.
Key words: hepatitis C; pegylated interferon; IL28B polymorphism; sustained viral response

Introduction

Genotype 1 hepatitis C infection (HCV) is the most common Hepatitis C infection, accounting for 46.2% of all HCV cases, approximately one-third of which occur in East Asia. [1]. Genotype 1 infection has been historically reported as being difficult to treat [2,3] until the advent of direct-acting antiviral agents (DAAs). DAAs are well tolerated and are an oral regimen, with multiple studies reporting sustained viral response rates (SVR) > 90% in Genotype 1 patients [4,5]. However, the accessibility of these direct-acting antiviral agents has been complicated by the high price of therapy [6]. Many times, use of these new drugs is either limited by individual patient’s ability to afford them in places where patients have to pay for their own medications or patients who already have significant complications from HCV infection even in countries with national healthcare schemes [7,8]. Data from Asia have shown favourable responses to pegylated interferon (PEG-IFN) and ribavirin in patients with hepatitis C and been attributed to favourable IL28B genotypes [9-11]. Hence, healthcare providers may still have to consider PEG-IFN in combination with ribavirin as a treatment option [12]. The patients, as well as the local health policy makers, can only make reasonable and informed decisions if they have enough knowledge about the success rates and what contributes to the success of conventional and new treatments. The decision is affected by the success rate experienced in local populations. In Singapore, which is made up of a diverse population with the ethnic distribution of 74.3% Chinese, 13.3% Malay and 9.1% Indians [13], data for SVR in patients treated with PEG-IFN and ribavirin are much needed.

It is known that certain host factors predict better response to therapy with PEG-IFN and ribavirin [11,14]. The difference in response rates between African-Americans and Caucasians is largely explained by genetic differences in the IL28B gene region on chromosome 19 [11,15]. The majority of African-Americans have either of the less favourable genotypes (CT or TT) [15]. The CT or TT genotype was associated with a 40% lower SVR rate compared with patients having the CC allele. The IL28B CC genotype, which is the favourable genotype, is the predominant genotype in China [16]. Singapore, which is a multi-ethnic country with a predominantly Chinese population, also demonstrates a high proportion of CC genotype [17].

In addition, the inosine triphosphate (ITPA) gene (rs1127354 and rs7270101) is known to provide protection against anaemia during therapy [18]. Patients who do not develop anaemia are more likely to comply and receive the full course of therapy, which is important as SVR increases with higher levels of dose compliance of PEG-IFN and ribavirin [19,20]. The ITPA variation is unknown in Singapore.

It could potentially be highly cost effective to screen patients for IL28B prior to determining which therapy to prescribe, especially in resource-poor countries and places in which patients have to pay for their medications out of pocket. Therefore, in this study, we aimed to determine the IL28B genotype and ITPA variations among HCV genotype 1 patients who have undergone therapy with PEG-IFN and ribavirin and their association with SVR in order to see if we can predict the response to therapy based on these two host factors.

Patients and methods

Patients

All patients with HCV genotype 1 who were previously treated with PEG-IFN and ribavirin at the Department of Gastroenterology and Hepatology at Singapore General Hospital between 2004 and 2015 were identified by available medical records. Patients were treated with PEG-IFN alfa-2a and weight-based ribavirin for 48 weeks. The dose of PEG-IFN alfa-2a was 180 μg subcutaneously per week, and the ribavirin dose was 1000 mg/day for patients weighing <75 kg and 1200 mg/day for patients weighing ≥75 kg. The patients were contacted by a letter inviting them to participate in the study. Blood samples for IL28B and ITPA genotyping were obtained from the patients who agreed to participate in the study. Medical records were reviewed for verification of the duration of therapy, response to therapy, development of anaemia and if erythropoietin was required during the treatment. Prior approval from the ethics committee was obtained from the ethics review board per Helsinki guidelines for human research.

Gene tests

Peripheral venous blood was collected from all participants in EDTA-containing tubes. Genomic DNA was extracted from 400 μl of whole blood using the Maxwell 16 DNA Purification Kit (Promega) on the Maxwell MDX 16 automatic DNA extraction instrument (Promega) per the manufacturer’s instructions. Finally, DNA was eluted with 400 μl elution buffer. DNA concentration was measured using Nanodrop spectrophotometer ND-1000 (Thermo Fisher Scientific). IL28B polymorphism (rs12979860, rs8099917) and ITPA variations (rs7270101, rs1127354) were tested using TaqMan® Assays (Applied Biosystems) per manufacturer’s instructions. Primers used are mentioned in the manufacturer’s protocol.

Definitions

SVR is defined as undetectable HCV RNA level using a sensitive assay 24 weeks after completion of therapy for hepatitis C. Anaemia was defined as either a decline in hemoglobin (Hb) of 3 g/dL or a drop of Hb levels to <10 g/dL. Treatment discontinuation was defined as patients who were unable to complete the 48-week course. Patients were defined as being cirrhotic if they met at least two out of three criteria (splenomegaly, caudate lobe hypertrophy or coarsened echotexture) on imaging or had a transient elastography reading >12.5 kPa.

Outcome measurement

The primary outcomes of the study were IL28B polymorphism and ITPA gene variation among GT1 HCV patients who underwent therapy with PEG-IFN, and ribavirin and their association with SVR. The secondary outcome was the incidence of discontinuation or interruption of treatment due to side effects.

Statistical analysis

Statistical analysis was carried out using SPSS 21.0 (Chicago, IL). Continuous variables are expressed as mean ± standard deviation (SD), while categorical variables are expressed as actual numbers and their percentages. Continuous variables were compared using analysis of variance, and categorical variables were compared using the chi-square test or Fisher exact test. A P value <0.05 was considered statistically significant.
RESULTS
Patient characteristics at initiation of treatment
There were 61 patients who had previously undergone treatment, and the SVR was 73.8% with mean age of 43.2 ± 12.0 years. Treatment discontinuation was seen in 14.8% (9/61) of patients. Out of these 61 patients, 42 (68.8%) patients agreed to participate in the study. The mean age of the study population was 45.6 ± 12.9 years at the time of treatment, and 83.3% of the patients were males. Demographic and clinical parameters of the 42 patients were presented in Table 1.

IL28B polymorphism and ethnicity
In keeping with the racial distribution in Singapore, 32/42 (76.1%) patients were Chinese, and 27/32 (84.3%) had a predominantly CC genotype (Table 2).

ITPA polymorphism, anaemia and treatment reduction
Eleven (26.1%) patients had ITPA AC genotype, 30 (71.4%) had CC genotype, and only one (2.3%) had AA genotype. Five (45.5%) of the patients with AC genotype developed clinically significant anaemia compared with 19 (63.3%) of the patients with CC genotype (P=0.302, Table 3). In such instances, these patients required either an attenuated dose of ribavirin or were started on erythropoietin.

The patients who developed anaemia were more likely to get a treatment reduction (11/24 vs 3/18, P=0.057). The median dosage of ribavirin was 800 mg/day over a course of 35 weeks in patients who had reduced dosages of ribavirin compared with 1000 mg/day over a course of 48 weeks for patients who received the full course of treatment.

Treatment response
In the 42 patients who agreed to participate in the study, SVR was seen in 28 (66.7%). Eight (19.0%) patients discontinued treatment due to the following reasons: two were lost to follow-up; two had failed early response to treatment (HCV RNA decrease <2 log) and were discontinued at week 24; four were intolerant of PEG-IFN and ribavirin; two developed symptomatic anaemia; one developed pancytopenia; and one perceived low mood. Six (14.3%) patients had a shortened duration of treatment due to missed dosages.

Thirty-three (78.6%) patients had IL28B C/C genotype, of whom 25 (75.8%) obtained SVR compared with only 3/9 (33.3%) non-C/C genotype patients who achieved SVR (P=0.041); however, neither anaemia nor treatment reduction was found to have an impact on SVR (Table 4).

Discussion
The field of chronic hepatitis C has been revolutionised by the appearance of the newer DAAs [21–24], but their very high costs have limited their accessibility. Nonetheless, chronic hepatitis C should be treated to avoid the burden of chronic liver disease [25–27]. Health authorities in various countries have tried to rationalise their health expenditure by confining its use to patients with severe liver disease as defined by degree of fibrosis or presence of cirrhosis [28,29]. However, treatment by which time may be too late to avoid the complications associated with chronic hepatitis C despite successful treatment [30]. There could perhaps be other criteria for rationalising the use of DAAs rather than just purely the severity of liver disease.

PEG-IFN and ribavirin should still be considered a viable combination in populations with favourable IL28B genotype [31]. It is known that IL28B genotypes can predict response to treatment with interferon and ribavirin to hepatitis C and that ITPA variant, which predicts the development of anaemia in patients on interferon [15,18], can have an impact on the total

| Table 1. Patient characteristics (N = 42) |
|------------------------------------------|
| Age (years) | 45.6 ± 12.9 |
| Male | 35 (83.3%) |
| Race | |
| Chinese | 32 (76.2%) |
| Malay | 4 (9.5%) |
| Indian | 2 (4.8%) |
| Other | 4 (9.5%) |
| Genotype | |
| 1a | 18 (42.9%) |
| 1b | 20 (47.6%) |
| 1 (indeterminate subtype) | 4 (9.5%) |
| Cirrhosis | 7 (20%) |
| Previous treatment | 0 (0%) |
| ALT (normal range 10–55 U/L) | 814 ± 42.1 |
| Hemoglobin (normal range 11.5–15.0 g/dL) | 14.8 ± 1.4 |
| WBC (normal range 4–10 x 10^9/L) | 5.8 ± 1.5 |
| Platelet (normal range 140–440 x 10^9/L) | 201 ± 68 |

ALT: alanine transaminase; WBC: white blood cell

| Table 2. IL28B polymorphism (rs12979860) and ethnicity |
|---------------------------------------------|
| Ethnicity | Polymorphism |
| CC | CT & TT |
| Chinese (N = 32) | 27 | 5 |
| Malay (N = 4) | 3 | 1 |
| Indian (N = 2) | 0 | 2 |
| Others (N = 4) | 3 | 1 |

| Table 3. ITPA Polymorphism (rs1127354) and anaemia |
|--------------------------------------------------------|
| Polymorphism | Anaemia | No anaemia |
| CC (N = 30) | 19 | 11 |
| AA (N = 1) | 0 | 1 |

| Table 4. Influence of IL28B polymorphism, anaemia and treatment reduction on sustained viral response (SVR) |
|----------------------------------------------------------|
| IL28B polymorphism | SVR | Failed SVR | P value |
|---------------------|-----|-----------|---------|
| CC (N = 33) | 25 (78.6%) | 8 (21.4%) | 0.041 |
| CT & TT (N = 9) | 3 (33.3%) | 6 (66.7%) | 0.508 |
| Anaemia | Yes (N = 24) | 17 (70.8%) | 7 (29.2%) | 1.000 |
| No (N = 18) | 11 (61.1%) | 7 (38.9%) | |
| Treatment reduction | Yes (N = 14) | 9 (64.3%) | 5 (35.7%) | |
| No (N = 28) | 19 (67.9%) | 9 (32.1%) | |
dose of ribavirin received during the course of treatment and thus impact the treatment outcome. Hence, it is reasonable to expect better SVR rates among patients with the favourable genotypes [9,10,32]. In the Western population, the SVR was 65% [4], even after adding a first generation DAA (Telaprevir) to the PEG-IFN and ribavirin combination, while the same treatment combination yielded a SVR rate of 87.7% in an Asian population [33].

In our cohort, there is a significantly higher SVR of 73.8% among patients with hepatitis C genotype 1 infection that is similar to Korea [9] and Taiwan [10]. This may be due to the IL28B CC polymorphism prevalent in our predominantly Chinese population [17]. Singapore comprises 74.3% Chinese, 13.3% Malays and 9.1% Indians [13]. Our study had a similar distribution, but the number of Malay (4/42) and Indian (2/42) patients in this study was too small for their results to be generalised across the Singaporean population.

Patients who develop anaemia are also given attenuated doses of ribavirin, which may affect treatment outcome [20]. However, it appears that 70.8% of patients in our population who develop anaemia still manage to achieve SVR. Treatment reduction also did not appear to have an impact on SVR, suggesting that the IL28B variants may have a larger impact on SVR than the ITPA variants.

One of the limitations of this study is that the sample size for data is relatively small. Our original cohort of 61 patients had a SVR of 73.8%, compared with the 42 patients who agreed to return for genotype testing (with a SVR of 66.7%). This is due to the fact that the group of patients who did not obtain SVR remained on follow-up and were more likely to agree to participate in the study. This small sample size may also underestimate the effects of ITPA analysis in the population.

IL28B genotyping can be useful for stratifying treatment of patients in populations with a reasonably high prevalence of IL28B CC genotype—and thus a reasonably favourable chance of SVR with conventional treatment in a substantial proportion of patients—and for identifying a smaller subgroup who most likely require the newer direct antiviral agents as their first-line treatment. The estimated cost of new DAA in Singapore is $65 000 to $96 000 for a course of treatment. Further cost-effective analysis needs to be done based on IL28B genotypes, and the role of pharmacogenetic testing in the management of patients with chronic hepatitis C needs to be determined in a resource-limited setting.

Conflict of interest statement: none declared.

References

1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;61:77–87.

2. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.

3. Bruno S, Cammà C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004;41:474–81.

4. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199–236.

5. Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C-infected patients. Hepatology 2016;64:405–14.

6. Andrieux-Meyer I, Cohn J, de Araujo ES, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 2015;3:e67–6.

7. Graham CS and Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res 2015;119:89–96.

8. Rosenthal ES and Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24.

9. Jung CH, Um SH, Kim TH, et al. Treatment response and long-term outcome of peginterferon α and ribavirin therapy in Korean patients with chronic hepatitis C. Gut Liver 2016;10:808–17.

10. Chen JY, Lin CY, Wang CM, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011;12:300–9.

11. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009;41:1100–4.

12. Kanda T, Nakamoto S and Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virol 2015;4:178–84.

13. Department of Statistics MoTI, Republic of Singapore,. Population Trends. 2014.

14. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha
and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.
15. Ge D. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
16. Dong ZX, Zhou HJ, Xiang XG, et al. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population. J Dig Dis 2015;16:90–7.
17. Poon KS, Ho SS, Tang JW, et al. Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping. J Clin Microbiol 2012;50:3353–5.
18. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405–8.
19. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061–9.
20. Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011;155:353–60.
21. Ledipasvir + sofosbувir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties. Prescrire Int 2015;24:285–9.
22. Bourliere M, Adhoute X, Ansaldi C, et al. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Exp Rev Gastroenterol Hepatol 2015;9:1483–94.
23. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420–9.
24. Zhang X. Direct anti-HCV agents. Acta Pharm Sin B 2016;6:26–31.
25. McDonald SA, Dahlui M, Mohamed R, et al. Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. PLoS One 2015;10:e0128091.
26. Leung N, Chu C, Tam JS. Viral hepatitis C in Hong Kong. Intervirology 2006;49:23–7.
27. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164–70.
28. Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 2016;176:65–73.
29. Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860–9.
30. Tandon N, Reddy KR, Lefebvre P, et al. Mo1030 Direct and Indirect Cost Burden of Chronic Hepatitis C Stratified by Liver Disease Severity in Privately-Insured Patients. Gastroenterology 2013;144:S-1017.
31. Olmedo DB, Cader SA and Porto LC. IFN-γ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. J Med Virol 2015;87:1702–15.
32. Mi Y, Gao YT, Jiao XL, et al. The role of interleukin-28b gene polymorphisms in Chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon 2014;14:e18793.
33. Kawaguchi Y, Iwane S, Kumagai T, et al. Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b. IntMed 2015;54:2551–60.
34. Martinot-Peignoux M, Maylin S, Moucari R, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antiviral Ther 2009;14:501–11.
35. Tontodonati M, Cento V, Polilli E, et al. May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics. New Microbiol 2015;38:491–7.
36. Huang CF, Yu ML, Kao JH, et al. Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol 2013;56:293–8.
37. Thornton K, Deming P, Manch RA, et al. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatol Int 2016;10:624–31.
38. Afshal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93.
39. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515–23.